

# CERTIFICATE

Survey of 24 October 2025

You have fulfilled the requirements of the External Quality Assessment with the following analysis

## Anticonvulsants 03 (871):

Validity 12 months:

Lacosamide

(R) analysis is subject to the RiliBÄK

**Customer:**  
**10042935**  
**MUDr.,PhD. Tomas Salek**  
**Krajska nemocnice T.Bata, a.s.**  
**Department of Clinical Biochemistry &**  
**Pharmacology**  
**Havlickovo nabrezi 600**  
**76275 Zlin**

Düsseldorf, 25 November 2025



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Prof. Dr. med. Werner Steimer  
(Adviser)

# CERTIFICATE OF PARTICIPATION

Survey of 24 October 2025

You have participated in the External Quality Assessment with the following analysis

## Anticonvulsants 03 (871):

Lacosamide

(R) analysis is subject to the RiliBÄK

**Customer:**  
**10042935**  
**MUDr., PhD. Tomas Salek**  
**Krajska nemocnice T. Bata, a.s.**  
**Department of Clinical Biochemistry &**  
**Pharmacology**  
**Havlickovo nabrezi 600**  
**76275 Zlin**

Düsseldorf, 25 November 2025



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Prof. Dr. med. Werner Steimer  
(Adviser)